FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerAntibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from Share XFDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerhttps://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/
Biotech Insight podcast: Overcoming planning challenges in oncologyThe first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges Share XBiotech Insight podcast: Overcoming planning challenges in oncologyhttps://pharmaphorum.com/podcast/biotech-insight-oncology-planning/
Genmab takes aims at immuno-oncology antibody conjugates with Bolt BioGenmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for Share XGenmab takes aims at immuno-oncology antibody conjugates with Bolt Biohttps://pharmaphorum.com/news/genmab-takes-aims-at-immuno-oncology-antibody-conjugates-with-bolt-bio/
Jan van de Winkel: Building Europe’s biotech powerhouse at GenmabJan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO Share XJan van de Winkel: Building Europe’s biotech powerhouse at Genmabhttps://pharmaphorum.com/views-and-analysis/jan-van-de-winkel-building-europes-biotech-powerhouse-at-genmab/
Genmab CEO discusses repurposing cancer treatmentsGenmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, Share XGenmab CEO discusses repurposing cancer treatmentshttps://pharmaphorum.com/news/genmab-could-spin-out-autoimmune-disease-unit-says-ceo-goes-with-feature/
Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerSeagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients Share XSeagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerhttps://pharmaphorum.com/news/seagen-and-genmab-file-trojan-horse-cancer-drug-with-fda/
Genmab axes development of AXL-targeting cancer drug enapotamab vedotinGenmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity Share XGenmab axes development of AXL-targeting cancer drug enapotamab vedotinhttps://pharmaphorum.com/news/genmab-axes-development-axl-targeting-cancer-drug-enapotamab-vedotin/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
J&J defends Darzalex with FDA approval for faster dosingJohnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that Share XJ&J defends Darzalex with FDA approval for faster dosinghttps://pharmaphorum.com/news/jj-defends-darzalex-with-fda-approval-for-faster-dosing/
